|
Name |
Xenoacremone D
|
Molecular Formula | C29H35NO5 | |
IUPAC Name* |
3,22-dihydroxy-10,12-dimethyl-15-oxa-23-azaheptacyclo[12.9.3.216,19.11,22.04,9.010,26.025,28]triaconta-5,16(27),17,19(26)-tetraene-24,29-dione
|
|
SMILES |
CC1CC(C)C2C(C1)C1C=CC3C(O)CC45CC(O)(Cc6ccc(cc6)OC2C1C3C4=O)NC5=O
|
|
InChI |
InChI=1S/C29H35NO5/c1-14-9-15(2)22-20(10-14)18-7-8-19-21(31)12-28-13-29(34,30-27(28)33)11-16-3-5-17(6-4-16)35-25(22)23(18)24(19)26(28)32/h3-8,14-15,18-25,31,34H,9-13H2,1-2H3,(H,30,33)/t14-,15+,18+,19-,20+,21-,22-,23+,24+,25+,28+,29-/m1/s1
|
|
InChIKey |
LRYAMUIPQBLDBG-QHHMGBMXSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 477.6 | ALogp: | 2.9 |
HBD: | 3 | HBA: | 5 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 95.9 | Aromatic Rings: | 8 |
Heavy Atoms: | 35 | QED Weighted: | 0.392 |
Caco-2 Permeability: | -4.849 | MDCK Permeability: | 0.00028022 |
Pgp-inhibitor: | 0.003 | Pgp-substrate: | 0.01 |
Human Intestinal Absorption (HIA): | 0.145 | 20% Bioavailability (F20%): | 0.015 |
30% Bioavailability (F30%): | 0.005 |
Blood-Brain-Barrier Penetration (BBB): | 0.389 | Plasma Protein Binding (PPB): | 96.18% |
Volume Distribution (VD): | 2.227 | Fu: | 3.09% |
CYP1A2-inhibitor: | 0.016 | CYP1A2-substrate: | 0.913 |
CYP2C19-inhibitor: | 0.405 | CYP2C19-substrate: | 0.904 |
CYP2C9-inhibitor: | 0.137 | CYP2C9-substrate: | 0.175 |
CYP2D6-inhibitor: | 0.014 | CYP2D6-substrate: | 0.089 |
CYP3A4-inhibitor: | 0.963 | CYP3A4-substrate: | 0.911 |
Clearance (CL): | 16.654 | Half-life (T1/2): | 0.046 |
hERG Blockers: | 0.028 | Human Hepatotoxicity (H-HT): | 0.212 |
Drug-inuced Liver Injury (DILI): | 0.678 | AMES Toxicity: | 0.021 |
Rat Oral Acute Toxicity: | 0.982 | Maximum Recommended Daily Dose: | 0.913 |
Skin Sensitization: | 0.01 | Carcinogencity: | 0.104 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.005 |
Respiratory Toxicity: | 0.854 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC005770 | 0.667 | D02FEM | 0.225 | ||||
ENC005135 | 0.636 | D0VA0I | 0.224 | ||||
ENC005769 | 0.598 | D03IKT | 0.217 | ||||
ENC005768 | 0.578 | D0W2EK | 0.214 | ||||
ENC003851 | 0.545 | D08PIQ | 0.211 | ||||
ENC005767 | 0.493 | D01XDL | 0.209 | ||||
ENC005366 | 0.489 | D0F1EX | 0.208 | ||||
ENC003606 | 0.489 | D0V9DZ | 0.203 | ||||
ENC003349 | 0.453 | D0I5DS | 0.203 | ||||
ENC004852 | 0.430 | D04SFH | 0.201 |